date:Apr 28, 2012
The trial, claimed to bethe longest human trial reported thus far using a resveratrol-containing product, found that levels of C-reactive protein (CRP), a well-established marker of inflammation, fell by 26%, report researchers in theThe American Journal of Cardiology.
The study was performed in people at high risk of cardiovascular disease (CVD) and the participants were also receiving statins. However, people in the placebo group did not exhibit the same beneficial reductions in inflammatory m